Cognitive function · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of MCI · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of dementia · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (Hypoglycaemia) · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Postoperative wound or systemic infection · participants undergoing surgery
Dexamethasone showed no clear difference in postoperative wound or systemic infection compared with control (moderate certainty).
1 finding from 1 review
Delayed wound healing · participants undergoing surgery
Dexamethasone showed no clear difference in delayed wound healing compared with control (low certainty).
1 finding from 1 review
Glycaemic response ‐ change from baseline to 2 to 12 hours postoperatively in patients without diabetes · participants undergoing surgery
1 finding from 1 review
Glycaemic response ‐ change from baseline to 10 to 24 hours after surgery in patients with diabetes · participants undergoing surgery
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk of or with apnea; preterm infants undergoing extubation
Methylxanthine probably leads to lower death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death at hospital discharge · preterm infants at risk for apnea
It is very uncertain whether methylxanthine changes death at hospital discharge compared with placebo or control (very low certainty).
1 finding from 1 review
Major neurodevelopmental disability at childhood · preterm infants at risk for apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
a) Cerebral palsy or gross motor disability · preterm infants at risk for apnea
Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
1 finding from 1 review
Developmental delay at ≥ 18 months · preterm infants at risk for apnea
Methylxanthine showed no clear difference in b) Developmental delay compared with placebo or control (moderate certainty).
1 finding from 1 review
Any apneic episodes · preterm infants at risk for apnea
Methylxanthine may leads to lower any apneic episodes compared with placebo or control (low certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · preterm infants at risk for apnea
Methylxanthine showed no clear difference in positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
1 finding from 1 review
Oxygen requirement at 36 weeks' postmenstrual age · preterm infants at risk for apnea
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
1 finding from 1 review
Death or major neurodevelopmental disability at 18 to 24 months · preterm infants with apnea
Methylxanthine showed no clear difference in death or major neurodevelopmental disability at 18 to 24 months compared with placebo or control (moderate certainty).
1 finding from 1 review
Death at hospital discharge · preterm infants with apnea
Methylxanthine showed no clear difference in death at hospital discharge compared with placebo or control (low certainty).
1 finding from 1 review